Compare Heron Therapeutics Inc (HRTX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Virgin Galactic Holdings, Inc. trades at $2.94 (market cap $456.30M). The key difference: Virgin Galactic Holdings, Inc. is far larger — about 6.2× Heron Therapeutics Inc's market cap, and Virgin Galactic Holdings, Inc. is more actively traded (4,518,834 versus 3,668,095). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| HRTX | SPCE | |
|---|---|---|
Market Cap | $74.04M | $456.30M |
Volume | 3,668,095 | 4,518,834 |
Sector | Health | Industrials |
52-Week High | $1.49 | $7.52 |
52-Week Low | $0.27 | $2.17 |
Typical Hold Time | 35 Days | 69 Days |
Enterprise Value | $180.78M | $420.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
SPCE trades at $2.94, down 4.23% today, reflecting a bearish technical outlook amid persistent fundamental challenges. The company continues to report significant losses, with a net income margin of -23,867.44% in 2025, though recent quarters have seen earnings beats. Cash flow remains negative, but trends show improvement, with a projected positive net cash flow of $25M in 2026. Analyst sentiment is mixed, with a Buy/Hold/Sell split of 29%/41%/29%.
The outlook remains high-risk due to ongoing cash burn and delayed commercial flights, but strong ticket demand and a path to positive cash flow by 2027 offer long-term potential. Investors face substantial volatility and dilution risks, requiring careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
